Every GLP-1 and muscle study from September 2026, synthesized into one cited review

What is inside

• Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance. (High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026-09-06 · Moscucci F et al.)
• Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss. (Diabetes, obesity & metabolism · 2026-09-01 · Stanton LA et al.)
• Increasing skeletal muscle mass and strength during incretin-based weight loss. (Obesity pillars · 2026-08-10 · Mendias CL, Awan TM)
• Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide. (Diabetes/metabolism research and reviews · 2026-01-01 · Al Ozairi E et al.)
• Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation. (Obesity pillars · 2026-07-15 · Joshi SR et al.)
• Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials. (Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026-07-13 · Vandoni M et al.)
• Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study. (Obesity pillars · 2026-06-29 · Babazadeh D et al.)
• The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review. (Obesity (Silver Spring, Md.) · 2026-07-12 · Saavedra JM et al.)
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. (Drugs · 2026-09-12 · Beaudart C et al.)
• The GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapy (Preprint · 2026-09-07 · Hungund S.)
• Metabolic Effects of a GLP-1 Analog Combined with Aerobic Training in Ovariectomized Rats. (Molecular and cellular endocrinology · 2026-09-11 · Selau B et al.)
• Weight Loss without Food Intake Suppression through Size-Dependent Retention of Anti-Inflammatory Nanomedicines. (ACS nano · 2026-01-01 · Medina NG et al.)
• Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery. (Journal article · 2026-09-10 · Abud GF, de Freitas EC, Stanford KI.)
• Why Do We Lose Bone During Weight Loss: Can It Be Prevented? (Journal article · 2026-09-09 · Shapses SA, McGuire BD.)
• Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. (Diabetes, obesity & metabolism · 2026-09-20 · Hjelmesæth J et al.)
• Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated with GLP-1 Receptor Agonists: A Real-World Experience. (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026-09-19 · Goñi JA et al.)
• GLP-1 Receptor Agonist Initiation Is Associated With Excess Skeletal Muscle Loss in Adults With Diabetes: A Prospective Population-Based MRI Study (Preprint · 2026-09-17 · Stambollxhiu E et al.)
• Effect of GLP-1 receptor agonist on nutrient intake: A narrative review. (Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026-09-17 · Fujioka K)
• Precise resistance training alleviates osteosarcopenia via the GLP-1/myostatin path: a 32-week randomized controlled trial and molecular mechanism study. (Archives of physiology and biochemistry · 2026-09-17 · Sun L et al.)
• Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome. (JCEM case reports · 2026-09-16 · Yovera-Aldana M, Manrique-Hurtado H, Umpierrez GE)
• Impact of Obesity, Sarcopenia, and Nutritional Status on Spine Surgery Patients. (The Journal of the American Academy of Orthopaedic Surgeons · 2026-05-22 · Daniels AH et al.)
• Creatine for glucagon-like peptide-1-associated muscle loss. (Clinical nutrition (Edinburgh, Scotland) · 2026-09-21 · Ostojic SM, Galyean S)
• An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss. (Proceedings of the National Academy of Sciences of the United States of America · 2026-09-25 · Thorne AK et al.)
• Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor. (Bioorganic & medicinal chemistry letters · 2026-09-27 · Bu X et al.)
• Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency. (Obesity (Silver Spring, Md.) · 2026-09-24 · Falahee B, Apovian CM, Istfan N)
• Improving Patient Outcomes by Bridging Bariatric and Body Contouring Surgery with Comprehensive Prehabilitation. (Plastic and reconstructive surgery. Global open · 2026-09-23 · Campbell CA et al.)
• Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes. (Osteoarthritis and cartilage · 2026-09-21 · Rombach J et al.)
• Aging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions. (Journal article · 2026-09-21 · Liu T, Hu Y.)
• Prehabilitation for Breast Reconstruction Surgery: A Practical and Evidence-based Guide. (Journal article · 2026-09-23 · Rezak K, Patel A, Knackstedt R.)

Every finding in this review is attributed to a specific study named in the guide, drawn from that month's research roundups. Where the evidence is a preprint, mixed, or thin, the guide says so instead of rounding up.